The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Volkov A.I.

Federal Center of Brain and Neurotechnology of Federal Medical-Biological Agency of Russia

Popova E.V.

Tambov branch of S.N. Fyodorov National Medical Research Center «MNTK «Eye Microsurgery»

New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire

Authors:

Volkov A.I., Popova E.V.

More about the authors

Read: 2797 times


To cite this article:

Volkov AI, Popova EV. New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7‑2):43‑47. (In Russ.)
https://doi.org/10.17116/jnevro202012007243

Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

References:

  1. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520-532.  https://doi.org/10.1016/S1474-4422(10)70064-8
  2. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129(Pt 3):584-594.  https://doi.org/10.1093/brain/awh721
  3. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606‐616.  https://doi.org/10.1093/brain/awl007
  4. Tremlett H, Yinshan Zhao, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314-324.  https://doi.org/10.1177/1352458507084264
  5. Inojosa H, Proschmann U, Akgun K, Ziemssen T. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. J Neurol. 2019 : 45-49;1.  https://doi.org/10.1007/s00415-019-09489-5
  6. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183-193.  https://doi.org/10.1016/S1474-4422(14)70256-X
  7. Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20(12):1654-1657. https://doi.org/10.1177/1352458514521517
  8. Skoog B, Tedeholm H, Runmarker B, Oden A, Andersen O. Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Relat Disord. 2014;3(5):584-592.  https://doi.org/10.1016/j.msard.2014.04.004
  9. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647-656.  https://doi.org/10.1038/nrneurol.2012.168
  10. Larochelle C, Uphaus T, Prat A, Zipp F. Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci. 2016;39(5):325-339.  https://doi.org/10.1016/j.tins.2016.02.001
  11. Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim Ch, Traboulsee A, Vollmer T. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(suppl 1):5-48. [FREE Full text] https://doi.org/10.1016/j.msard.2016.07.003
  12. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.  https://doi.org/10.1002/ana.22366
  13. Ziemssen T, Tolley C, Bennett B, Kilgariff S, Jones E, Pike J, Tomic D, Lahoz R. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians’ and patients’ views. Mult Scler Relat Disord. 2020;38:101861. https://doi.org/10.1016/j.msard.2019.101861
  14. Tolley C, Piani-Meier D, Bentley S, Bennett B, Jones E, Pike J, Dahlke F, Tomic D, Ziemssen T. A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm. JMIR Med Inform. 2020;8(4):e17592. https://doi.org/10.2196/17592
  15. Ziemssen T, Piani-Meier D, Bennett B, Johnson Ch, Tinsley K, Trigg A, Hach Th, Dahlke Fr, Tomic D, Tolley Ch, Freedman MS. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. J Med Internet Res. 2020;22(2):e16932. Published 2020 Feb 12.  https://doi.org/10.2196/16932
  16. Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh CM, Hoffmann O, Oreja-Guevara C, Cedeño RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Hach Th, Piani-Meier D, Burton J. Real-World Findings of Usability and Usefulness of Multiple Sclerosis Progression Discussion Tool: A Physician-Completed Digital Tool to Evaluate Early Signs of Disease Progression. International Journal of MS Care. 2020;22:2:86.  https://doi.org/10.7224/1537-2073-22.s2.1
  17. Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58. Published 2014 Mar 25.  https://doi.org/10.1186/1471-2377-14-58
  18. Rocca MA, Battaglini M, Benedict RH, De Stefano N, Geurts JJ, Henry RG, Horsfield MA, Jenkinson M, Pagani E, Filippi M. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology. 2017;88(4):403‐413.  https://doi.org/10.1212/WNL.0000000000003542
  19. Pontillo G, Cocozza S, Lanzillo R, Russo C, Stasi MD, Paolella C, Vola EA, Criscuolo C, Borrelli P, Palma G, Tedeschi E, Morra VB, Elefante A, Brunetti A. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study. AJNR Am J Neuroradiol. 2019;40(1):99‐106.  https://doi.org/10.3174/ajnr.A5915
  20. Barro Ch, Benkert P, Disanto G, Tsagkas Ch, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera Cr, Yaldizli O, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141(8):2382‐2391. https://doi.org/10.1093/brain/awy154

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.